Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Meningioma
100%
Tumor
46%
Neurofibromatosis Type 1 (NF-1)
44%
Glioblastoma
43%
Neurofibromatosis Type I
42%
IDH-mutant Glioma
36%
Glioma
36%
Overall Survival
35%
Malignant Peripheral Nerve Sheath Tumor (MPNST)
35%
Histopathological Features
30%
DNA Methylation (DNAm)
27%
Radiotherapy
26%
Genetic Modification
24%
Extent of Resection
24%
Clinical Outcomes
23%
Peripheral Nerve Sheath Tumor
23%
Gross Total Resection
23%
Clinical Features
21%
Schwannoma
18%
Molecular Testing
18%
DNA Methylation Profiling
17%
World Health Organization Grade
17%
Central Nervous System Tumors
16%
Central Nervous System
16%
Preoperative Patients
16%
Genetic Events
16%
Metagenomic Next-generation Sequencing (mNGS)
16%
Physical Health-related Quality of Life
16%
Short-term Postoperative Outcomes
16%
SOX10
16%
Molecular Classification
16%
HIV-associated Neurocognitive Disorders
16%
Brain Tumor Patients
16%
Surgical Outcomes
16%
Treatment Response
16%
ERK Pathway
15%
Tumor Cells
14%
Resection
14%
Isocitrate Dehydrogenase 1 (IDH1)
14%
MEK Inhibitor (MEKi)
14%
Molecular Features
14%
Newly Diagnosed
13%
Cardiac Magnetic Resonance Imaging (cMRI)
13%
Metastasis
13%
Tumor Microenvironment
13%
Leptomeningeal Metastasis
13%
Immunoreactivity
12%
Copy number Alterations
12%
Stem Cells
12%
Sarcoma
12%
Medicine and Dentistry
Neoplasm
78%
Ganglioglioma
63%
Genetics
63%
Glioblastoma
59%
Tumor
54%
Meningioma
52%
Neurofibromatosis Type I
50%
Malignant Peripheral Nerve Sheath Tumor
40%
Nerve Sheath Tumor
34%
Peripheral Nerve
33%
Intracranial Tumor
30%
Central Nervous System Tumor
29%
Biopsy Technique
28%
Neurinoma
25%
Next Generation Sequencing
25%
Overall Survival
24%
Central Nervous System
23%
Radiation Therapy
22%
Magnetic Resonance Imaging
18%
Metastatic Carcinoma
17%
Malignant Neoplasm
17%
Chemoradiotherapy
17%
Quality of Life
16%
MEK Inhibitor
14%
Promoter Region
13%
Temozolomide
13%
Cyclin Dependent Kinase Inhibitor 2A
13%
Biological Product
12%
Treatment Response
12%
Gene Mutation
11%
Targeted Therapy
11%
Connective Tissue Cancer
11%
Histology
11%
Immunoreactivity
11%
Recurrent Disease
11%
Methylation
10%
DNA Methylation
10%
Malignant Transformation
10%
Clinical Management
10%
Odds Ratio
10%
Diseases
10%
Cancer
9%
Schwann Cell
9%
Retrospective Study
9%
RNA Sequence
9%
Neuro-Oncology
9%
Oligodendroglioma
9%
Biological Marker
9%
Gliosarcoma
9%
Immunohistochemistry
9%
